Dister R E, Harris M G
University of California, School of Optometry, Berkeley 94720.
J Am Optom Assoc. 1990 Mar;61(3):212-4.
The U.S. Food and Drug Administration (FDA) recently sent contact lens practitioners a letter advising them that the FDA had asked manufacturers to indicate a maximum recommended wearing time of 7 days for cosmetic extended wear soft contact lenses. This paper discusses the authority of the FDA and the legal consequences of the FDA's "7-day Letter." Congress has authorized the FDA to enact rules, guidelines and recommendations. The 7-day letter does not appear to be any of the above. However, it does have a significant effect on contact lens practitioners' professional responsibilities and legal obligations because the letter has led to changes in product labeling and the standard of care for extended wear patients. Practitioners would be wise to give careful consideration to any deviation from the FDA's recommendation and the provisions of the product labeling. As any deviation will likely impose greater legal responsibility on the practitioner, the special circumstances that justify the deviation should be thoroughly documented in an informed consent agreement.
美国食品药品监督管理局(FDA)最近致函隐形眼镜从业者,告知他们FDA已要求制造商标明美容性长戴型软性隐形眼镜的最大推荐佩戴时间为7天。本文讨论了FDA的权限以及FDA“7日函件”的法律后果。国会已授权FDA制定规则、指南和建议。“7日函件”似乎不属于上述任何一种。然而,它确实对隐形眼镜从业者的职业责任和法律义务产生了重大影响,因为该函件导致了产品标签的变化以及长戴型患者护理标准的改变。从业者明智的做法是仔细考虑任何偏离FDA建议和产品标签规定的情况。由于任何偏离都可能给从业者带来更大的法律责任,因此应在知情同意协议中充分记录证明这种偏离合理的特殊情况。